Could a diabetes drug heal Crohn's gut damage?
NCT ID NCT06976853
First seen Jun 06, 2026
Summary
This study tests tirzepatide, a drug used for diabetes, in 60 adults with Crohn's disease who have active inflammation in the small bowel despite other treatments. The goal is to see if tirzepatide can heal the gut lining better than switching to another standard biologic therapy. Researchers will check healing via colonoscopy and track side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN DISEASE (CD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cedars-Sinai Medical Center
NOT_YET_RECRUITINGBeverly Hills, California, 90211, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Icahn School of Medicine at Mount Sinai
RECRUITINGNew York, New York, 10029, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tirzepatide
What this could lead to
If successful, tirzepatide could offer a new option for healing intestinal damage in Crohn's disease patients who don't respond to current treatments.
What could go wrong
This is an early Phase 2 trial with only 60 participants, so results may not apply to everyone. Tirzepatide may cause side effects like injection-site reactions or gastrointestinal issues.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.